GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

GSK Pharmaceuticals India focuses on affordable general medicine access amidst premiumisation trend, discussed by managing ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

UK pharma group posts ‘statistically significant’ trial results for treatment combined with Blenrep pulled in 2022 ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Read more: UKG's longtime CFO to step down, successor named Loesch was previously president and CCO at Intrommune Therapies ...

Though prescribing climate-friendly dry powder inhalers is environmentally sound, some experts warn certain patients may be ...

Haleon’s Robitussin and GSK’s RSV vaccine Arexvy. Robitussin had the lowest estimated national TV ad spend at $4.4 million.

GSK has spent slightly more on lobbying this year compared with 2023. The company spent $3.87 million in the first three ...